Viewing data from:

CEFPODOXIME PROXETIL

ANDA

CEFPODOXIME PROXETIL | A065082 | SUN PHARMACEUTICAL INDUSTRIES LTD

2 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Cefpodoxime Proxetil (2023)

Total Spending

$24.3M

Total Claims

402,345

Beneficiaries

330,545

Avg Cost/Unit

$3.83

Spending Trend

$16.5M(2019)→$16.0M(2020)→$16.9M(2021)→$20.4M(2022)→$24.3M(2023)

YoY Change:-8.9%

5yr CAGR:-5.1%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain8 active DMFs2 inactive

7 active API suppliers hold Drug Master Files for this ingredient.

ORCHID PHARMA LTDCEFPODOXIME PROXETIL USP (NON-STERILE BULK)

DMF 185052005

APITORIA PHARMA PRIVATE LTDCEFPODOXIME PROXETIL USP

DMF 189412005

SANDOZ GMBHCEFPODOXIME PROXETIL

DMF 200762006

PURE AND CURE HEALTHCARE PRIVATE LTDCEFPODOXIME PROXETIL

DMF 235722010

NECTAR LIFESCIENCES LTDCEFPODOXIME PROXETIL USP

DMF 270712014

COVALENT LABORATORIES PRIVATE LTDCEFPODOXIME PROXETIL USP

DMF 297912015

QILU ANTIBIOTICS PHARMACEUTICAL CO LTDCEFPODOXIME PROXETIL

DMF 345022020

APITORIA PHARMA PRIVATE LTDCEFPODOXIME PROXETIL USP (PROCESS II)

DMF 395412024

SUN PHARMACEUTICAL INDUSTRIES LTDInactiveCEFPODOXIME PROXETIL USP

DMF 151922000

SANDOZ PRIVATE LTDInactiveCEFPODOXIME PROXETIL

DMF 165422003

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Apr 9, 2003	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — EQ 50MG BASE/5ML

0 patents0 exclusivities▴

FOR SUSPENSION;ORAL | Approved: May 31, 2002

No patent or exclusivity listings for this strength.

#002 — EQ 100MG BASE/5ML

0 patents0 exclusivities▾

FOR SUSPENSION;ORAL | Approved: May 31, 2002